Eveotox® Recombinant type A botulinum toxin is a next-generation recombinant type A botulinum toxin manufactured through genetic engineering in E. coli. The recombinant process enhances purity, safety, and clinical performance, setting a new benchmark in neurotoxins. It is widely applied in both neurological therapeutics, offering physicians a safer, more consistent, and reliable treatment option.

Specifications    50U / 100U / 200U

Product Features

• New generation of botulinum toxin, Manufacture via Genetic Engineering
• Single active component (150kDa), better clinical safety
• Meets the highest global activity standards
• High purity（＞0%）by HPLC
• High batch-to-batch consistency

Indications

• Treatment of post-stroke upper limb spasticity (elbow, wrist, or hand) in adults.

• Treatment of moderate to severe glabellar lines in adults.
• Treatment of post-stroke lower limb spasticity in adults
• Treatment of axillary hyperhidrosis in adults
• Treatment of eyelid spasm in adults

Clinical Trial Results

• Clinical trials demonstrated that Eveotox® achieved all predefined primary endpoints in efficacy, safety, and immunogenicity. Its overall performance was superior to the control group, validating its clinical advantages as a next-generation botulinum toxin.